This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Pompe Disease
  • /
  • AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Dis...
Clinical trial

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

Read time: 1 mins
Last updated:30th May 2022
Status: Recruiting
Identifier: NCT03533673
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

Brief Summary:
Open-label, ascending dose trial of ACTUS-101 administered intravenously.

Detailed Description:
This study will be a prospective, open-label trial designed to objectively assess the safety and bioactivity of ACTUS-101 in subjects diagnosed with Pompe disease, which is caused by a defect in acid α-glucosidase (GAA) gene. ACTUS-101 is intended to enable expression of a functional copy of the GAA gene in subject's hepatocytes.

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 13 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of the Safety of AAV2/8-LSPhGAA (ACTUS-101) in Late-onset Pompe Disease
Actual Study Start Date: December 17, 2018
Estimated Primary Completion Date: April 2025
Estimated Study Completion Date: April 2028

- Experimental: Cohort 1
- Experimental: Cohort 2
- Experimental: Cohort 3
- Experimental: Cohort 4
- Experimental: Cohort 5

Category Value
Study type(s) Interventional
Estimated enrolment 13
Actual Study start date 17 December 2018
Estimated study completion date 01 April 2028

View full details